Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline
Cellectar Biosciences (CLRB) reported Q2 2026 results. Cash and cash equivalents were $34.0M as of June 30, 2026, funding operations into Q2 2027. R&D rose to $4.6M from $2.4M a year earlier; net loss was $6.9M, or $0.57/share. Pipeline progress includes Phase 3 prep for Iopofosine I 131 in Waldenström macroglobulinemia and Phase 1b enrollment for CLR 125 in triple-negative breast cancer.
How this was made
The 30-second read
Why it matters
The Q2 release combines balance-sheet runway (cash into Q2 2027) with specific clinical execution milestones (Phase 3 site activation and first dosing expected early 2027) and a Phase 2b efficacy snapshot (87.5% overall response rate, 16-month median duration).
Market read
Traders can update CLRB’s probability-weighted pipeline outlook using the Phase 3 timeline and cash runway, while monitoring burn rate and dilution risk into 2027.
What to watch
The article does not quantify trial enrollment pace, cost of Phase 3, or financing plans beyond the stated runway, which are key for near-term downside risk.
Background
Cellectar is a clinical-stage oncology biotech developing targeted phospholipid drug conjugate radiotherapeutics, including Iopofosine I 131 for Waldenström macroglobulinemia (WM).
Ticker impact
Cellectar reported Q2 2026 results with $34.0M cash, higher R&D, and Phase 3 confirmatory trial preparations for Iopofosine I 131 in WM.
Bias modestly positive, with volatility around clinical milestone execution and NDA timing (mid-2027).
The article provides primary financial datapoints (cash, expenses, net loss) plus specific development timing and response-rate results from Phase 2b, which can re-rate probability-weighted outcomes, though it is not a regulatory decision or funding event.
Market effects
Reinforces investor focus on cash runway and progression from Phase 2b to Phase 3 in oncology radiotherapeutics, potentially supporting sentiment for similar small-cap clinical-stage names.
Limited direct regional spillover; primarily affects US small-cap biotech sentiment.
Low global relevance beyond oncology radiotherapeutics and rare-blood-cancer trial execution expectations.
Counterpoint
Despite the Phase 3 plan, the company still reports a widening R&D spend and ongoing net losses, so the stock may remain driven by dilution risk rather than clinical optimism.
Key entities
- companyCellectar Biosciences, Inc.
Reported Q2 2026 financial results and provided pipeline updates for Iopofosine I 131 and CLR 125.
- drug_programIopofosine I 131
PDC radiotherapeutic for WM; Phase 3 confirmatory trial preparations underway with first dosing expected early 2027 and NDA planned mid-2027.
- drug_programCLR 125
Iodine-125 Auger-emitting program; initiated enrollment and dosed first patients in a Phase 1b trial for refractory triple negative breast cancer.
